−3.7%
since Sep 29
The idea
I believe personalized medicine, treatments built around your own tumor or DNA, becomes a normal part of care over the next decade or two, not just a Covid-era exception. Since nobody can call which specific drug wins its trials, most of the basket sits in the sequencing, lab tools, and manufacturing suppliers who get paid regardless of whose vaccine succeeds, with smaller slices in the platform makers, diagnostics companies, and big pharma partners for balance.
What it owns
- Suppliers of instruments, reagents, and analytical tools used across drug discovery, diagnostics, and manufacturing, positioned to capture value regardless of which specific therapy succeeds. · DanaherIt supplies bioprocessing and diagnostics tools that every genetic medicine maker purchases, collecting revenue across the ecosystem regardless of which program succeeds., Thermo Fisher ScientificIt provides instruments, reagents, and contract manufacturing across nearly every genetic medicine program, capturing value as the sector expands., IlluminaIts sequencers read the tumor genomes that personalized vaccines are designed from, positioning it as infrastructure for the entire approach., Agilent TechnologiesIt supplies analytical and quality-control instruments that drug developers and diagnostics labs use daily, capturing growth across the sector without picking individual winners., Twist BioscienceIt manufactures synthetic DNA that vaccine designers, gene editors, and sequencing panels are built from, serving as a raw ingredient across the entire field., 10x GenomicsIt sells single-cell and spatial analysis tools that researchers use to understand tumors and immune responses at high resolution, feeding the science underlying personalized therapy design.26%
- Large pharmaceutical companies with committed oncology and genetic medicine pipelines, positioned to benefit from precision medicine adoption without building the platforms themselves. · Merck & CoMerck shares upside from its mRNA cancer vaccine partnership with Moderna through its oncology franchise without depending entirely on the program's success., AstraZenecaIt has committed substantially to targeted cancer drugs matched to a patient's tumor genetics, embedding precision medicine into its commercial strategy., NovartisIt already commercializes gene therapies and RNA-based drugs, demonstrating that large pharmaceutical companies can build profitable genetic medicine franchises., SanofiIt has committed billions to mRNA vaccines and immunology after acquiring Translate Bio, making it the large pharmaceutical company most explicitly extending the platform beyond its initial indication.22%
- Companies developing programmable genetic medicine platforms including mRNA, RNA interference, and gene editing, with approved or late-stage programs showing commercial viability. · ModernaIt is advancing individualized cancer vaccines in late-stage trials as proof that mRNA functions as a broad platform beyond its initial indication., BioNTechIt built its foundation on individualized cancer immunotherapy before Covid and maintains a broad oncology pipeline with substantial cash reserves to advance it., Alnylam PharmaceuticalsIt has multiple approved RNA-silencing drugs on the market, providing the strongest commercial evidence that programmable genetic medicine operates as a real business., CRISPR TherapeuticsIt has Casgevy, the first CRISPR medicine approved, and a pipeline targeting cancer and heart disease, representing the highest-risk segment of programmable genetic medicine., Arcturus TherapeuticsIt is developing self-amplifying mRNA that functions at lower doses, with approved vaccines and partnered programs advancing through its pipeline.20%
- Suppliers of components, consumables, and infrastructure for manufacturing and delivering genetic medicines and biologics at scale. · West Pharmaceutical ServicesIt manufactures the stoppers, seals, and delivery components that every injectable biologic and mRNA vaccine requires, scaling with approved genetic medicines., RepligenIt sells filtration and purification equipment used to manufacture biologics and mRNA, with consumables repurchased across every production batch., AvantorIt distributes everyday chemicals, single-use kits, and lab supplies that biopharma production depends on, tracking sector activity independent of individual drug outcomes., Maravai LifeSciencesIt produces CleanCap and critical inputs for mRNA manufacturing itself, representing the most direct supplier exposure to mRNA becoming a standard drug class.13%
- Companies providing genomic testing and data analytics that identify patients for personalized treatment and monitor therapy response. · NateraIts Signatera test detects residual tumor DNA in blood, determining which patients receive personalized vaccines and whether treatment worked., Guardant HealthIt profiles cancer from a blood draw, functioning as the front door to personalized treatment by identifying which patients match which therapies., Tempus AIIt layers genomic and clinical data into treatment recommendations and trial matching, providing the software infrastructure personalized medicine requires to scale beyond academic centers.11%
- Cash8%